BIOLINERX Trademark

Trademark Overview


On Monday, May 29, 2023, a trademark application was filed for BIOLINERX with the United States Patent and Trademark Office. The USPTO has given the BIOLINERX trademark a serial number of 79377712. The federal status of this trademark filing is REGISTERED as of Tuesday, August 27, 2024. This trademark is owned by BioLineRx Ltd.. The BIOLINERX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical product development services, namely, pharmaceutical product development through the discovery of compounds that helps for the treatment of a variety of diseases and symptoms; pharmaceutical product development services for a wide variety of diseases and symptoms, namely, neuropathic pain, acute kidney injury, inflammatory bowel disease, adult diabetes, weight loss among cancer patients, bacterial infections, rheumatoid arthritis, celiac disease, psoriasis, solid cancerous tumors, myocardial infarction, schizophrenia and prostate cancer; pharmaceutical product development services of new compounds for use in medicines for oncology patients; pharmaceutical research services; research and development services in the field of biotechnology
biolinerx

General Information


Serial Number79377712
Word MarkBIOLINERX
Filing DateMonday, May 29, 2023
Status700 - REGISTERED
Status DateTuesday, August 27, 2024
Registration Number7484132
Registration DateTuesday, August 27, 2024
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, June 11, 2024

Trademark Statements


Description of MarkThe mark consists of the stylized wording "BIOLINERX" with the wording "BIOLINE" in navy blue and the wording "RX" in light blue. The letter "L" extends below the letters "INERX", and goes from navy blue to light blue.
Description of the Colors Claimed"bioLine" in navy blue, "rx" in light blue.
Indication of Colors claimedThe colors navy blue and light blue are claimed as a feature of the mark.
Goods and ServicesPharmaceutical product development services, namely, pharmaceutical product development through the discovery of compounds that helps for the treatment of a variety of diseases and symptoms; pharmaceutical product development services for a wide variety of diseases and symptoms, namely, neuropathic pain, acute kidney injury, inflammatory bowel disease, adult diabetes, weight loss among cancer patients, bacterial infections, rheumatoid arthritis, celiac disease, psoriasis, solid cancerous tumors, myocardial infarction, schizophrenia and prostate cancer; pharmaceutical product development services of new compounds for use in medicines for oncology patients; pharmaceutical research services; research and development services in the field of biotechnology

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 1, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBioLineRx Ltd.
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressIL

Party NameBioLineRx Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressIL

Party NameBioLineRx Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressIL

Trademark Events


Event DateEvent Description
Friday, September 1, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 15, 2024ASSIGNED TO EXAMINER
Thursday, August 31, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, September 5, 2023APPLICATION FILING RECEIPT MAILED
Sunday, January 28, 2024LIMITATION OF GOODS RECEIVED FROM IB
Tuesday, February 20, 2024NON-FINAL ACTION WRITTEN
Wednesday, March 13, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, May 7, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 21, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, March 12, 2024REFUSAL PROCESSED BY MPU
Sunday, March 17, 2024LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Tuesday, April 2, 2024REFUSAL PROCESSED BY IB
Tuesday, May 7, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 7, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 7, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, May 7, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, May 7, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, May 7, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 7, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 7, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, May 22, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 11, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 11, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, May 8, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 27, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, August 27, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Friday, November 29, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Saturday, February 15, 2025FINAL DISPOSITION NOTICE SENT TO IB
Saturday, February 15, 2025NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Saturday, March 8, 2025FINAL DECISION TRANSACTION PROCESSED BY IB
Saturday, February 15, 2025FINAL DISPOSITION PROCESSED
Sunday, January 26, 2025NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, January 27, 2025NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB